Black Diamond Therapeutics Inc (BDTX)
4.60
-0.09
(-1.92%)
USD |
NASDAQ |
Jun 26, 14:14
Black Diamond Therapeutics Enterprise Value: 148.70M for June 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 25, 2024 | 148.70M |
| June 24, 2024 | 158.83M |
| June 21, 2024 | 157.14M |
| June 20, 2024 | 165.01M |
| June 18, 2024 | 184.15M |
| June 17, 2024 | 192.59M |
| June 14, 2024 | 220.72M |
| June 13, 2024 | 231.97M |
| June 12, 2024 | 235.91M |
| June 11, 2024 | 228.03M |
| June 10, 2024 | 172.33M |
| June 07, 2024 | 176.83M |
| June 06, 2024 | 146.45M |
| June 05, 2024 | 146.45M |
| June 04, 2024 | 156.01M |
| June 03, 2024 | 150.95M |
| May 31, 2024 | 153.76M |
| May 30, 2024 | 152.64M |
| May 29, 2024 | 152.07M |
| May 28, 2024 | 149.26M |
| May 24, 2024 | 159.95M |
| May 23, 2024 | 151.51M |
| May 22, 2024 | 168.39M |
| May 21, 2024 | 164.45M |
| May 20, 2024 | 160.51M |
| Date | Value |
|---|---|
| May 17, 2024 | 158.83M |
| May 16, 2024 | 179.64M |
| May 15, 2024 | 190.90M |
| May 14, 2024 | 207.78M |
| May 13, 2024 | 219.03M |
| May 10, 2024 | 228.60M |
| May 09, 2024 | 264.61M |
| May 08, 2024 | 275.30M |
| May 07, 2024 | 289.93M |
| May 06, 2024 | 300.51M |
| May 03, 2024 | 250.41M |
| May 02, 2024 | 230.98M |
| May 01, 2024 | 194.73M |
| April 30, 2024 | 177.39M |
| April 29, 2024 | 192.89M |
| April 26, 2024 | 194.20M |
| April 25, 2024 | 153.23M |
| April 24, 2024 | 150.60M |
| April 23, 2024 | 147.98M |
| April 22, 2024 | 148.50M |
| April 19, 2024 | 161.11M |
| April 18, 2024 | 163.21M |
| April 17, 2024 | 184.22M |
| April 16, 2024 | 167.41M |
| April 15, 2024 | 159.01M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-125.30M
Minimum
May 25 2022
1.342B
Maximum
Jul 01 2020
255.99M
Average
78.59M
Median
Enterprise Value Benchmarks
| Abbott Laboratories | 191.68B |
| Johnson & Johnson | 361.65B |
| Verastem Inc | 26.78M |
| Gritstone Bio Inc | 72.21M |
| CARISMA Therapeutics Inc | -9.572M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.22M |
| Total Expenses (Quarterly) | 20.25M |
| EPS Diluted (Quarterly) | -0.35 |
| Earnings Yield | -36.09% |